“…6,8,9,[21][22][23] No systematic vaccine-induced CD8 + T cell response was detected in PBMCs in our study, which was consistent with other studies that showed RTS,S/AS induces little or no detectable CD8 + T cell response. 6,11,21,24,25 The anti-CS humoral immune responses in this study tended to be lower than those observed following administration of 3 doses of RTS,S/AS01 or RTS,S/AS02 to malaria-experienced children in Africa 13,14 but higher than those in African adults in a high malaria transmission area. 12 Overall, in all studies including the present trial, RTS,S/AS formulations produced robust anti-CS antibody responses, with the AS01 adjuvanted vaccine inducing higher responses than the AS02 adjuvanted formulation.…”